tiprankstipranks
Perrigo Company Reports Solid Q3 2024 Financial Results
PremiumCompany AnnouncementsPerrigo Company Reports Solid Q3 2024 Financial Results
4M ago
Perrigo reports Q3 adjusted EPS 81c, consensus 81c
Premium
The Fly
Perrigo reports Q3 adjusted EPS 81c, consensus 81c
4M ago
Perrigo backs FY24 adjusted EPS view $2.50-$2.65, consensus $2.56
Premium
The Fly
Perrigo backs FY24 adjusted EPS view $2.50-$2.65, consensus $2.56
4M ago
Perrigo names David Ball as Chief Brand and Digital Officer
PremiumThe FlyPerrigo names David Ball as Chief Brand and Digital Officer
6M ago
Perrigo Announces Voluntary Recall, Maintains Fiscal Outlook
Premium
Company Announcements
Perrigo Announces Voluntary Recall, Maintains Fiscal Outlook
7M ago
Perrigo backs FY24 adjusted EPS view $2.50-$2.65, consensus $2.25
Premium
The Fly
Perrigo backs FY24 adjusted EPS view $2.50-$2.65, consensus $2.25
7M ago
Perrigo Completes HRA Pharma Rare Diseases Sale to Esteve
PremiumCompany AnnouncementsPerrigo Completes HRA Pharma Rare Diseases Sale to Esteve
8M ago
Perrigo completes divestment of HRA Pharma Rare Diseases business to Esteve
Premium
The Fly
Perrigo completes divestment of HRA Pharma Rare Diseases business to Esteve
8M ago
Perrigo price target lowered to $36 from $39 at Piper Sandler
Premium
The Fly
Perrigo price target lowered to $36 from $39 at Piper Sandler
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100